中国药物经济学2025，Vol.20Issue(9)：30-33,42,5.DOI:10.12010/j.issn.1673-5846.2025.09.005
白芍总苷胶囊治疗类风湿性关节炎的成本-效果分析
Cost-effectiveness Analysis of Total Glucosides of White Peony Capsules in the Treatment of Rheumatoid Arthritis
黄正明 1栗占国 2赵岩 3伍沪生 4刘燕鹰 5杨新波 1洪舟6
作者信息
- 1. 中国医药教育协会,北京 100071
- 2. 北京大学人民医院风湿免疫科,北京 100044
- 3. 北京协和医院风湿免疫科,北京 100730
- 4. 北京积水潭医院风湿免疫科,北京 102208
- 5. 北京友谊医院风湿免疫科,北京 100050
- 6. 宁波天然植物提取协会,浙江 宁波 315101
- 折叠
摘要
Abstract
Objective To evaluate the pharmacoeconomic advantages of Total Glucosides of White Paeony Capsules over hydroxychloroquine in the treatment of rheumatoid arthritis(RA).Methods From the perspective of the healthcare system,a decision tree model was constructed using Microsoft Excel 2019 software to simulate the total costs and clinical outcomes of using Total Glucosides of White Paeony Capsules alone versus hydroxychloroquine alone in the treatment of RA.Incremental analysis and one-way sensitivity analysis were performed.The cost data were sourced from 2022 price websites,while the efficacy data were obtained from literature.Results The basic analysis results show that the use of Total Glucosides of White Paeony Capsules alone has a cost advantage over hydroxychloroquine alone(476.11 yuan vs.766.08 yuan),and its clinical efficacy is better(87.67%vs.80.28%),which is an absolute advantage option.The results of univariate sensitivity analysis indicated that the top three parameters that had the most significant impact on the incremental cost-effectiveness ratio(ICER)were,in sequence,the effective rate of Total Glucosides of White Paeony Capsules,the effective rate of hydroxychloroquine,and the treatment cost of hydroxychloroquine.Conclusion Compared with hydroxychloroquine,Total Glucosides of White Paeony Capsules have a lower cost and better effect in the treatment of RA,and thus have an economic advantage.关键词
白芍总苷胶囊/羟氯喹/类风湿性关节炎/成本-效果Key words
Total Glucosides of White Paeony Capsules/Hydroxychloroquine/Rheumatoid arthritis/Cost-effectiveness分类
医药卫生引用本文复制引用
黄正明,栗占国,赵岩,伍沪生,刘燕鹰,杨新波,洪舟..白芍总苷胶囊治疗类风湿性关节炎的成本-效果分析[J].中国药物经济学,2025,20(9):30-33,42,5.
